  A variety of microparticles have been proposed for the sustained and
localized delivery of drugs whit the objective of increasing therapeutic
indexes by circumventing filtering organs and biological barriers. Yet, the
geometrical, mechanical and therapeutic properties of such microparticles
cannot be simultaneously and independently tailored during the fabrication
process in order to optimize their performance. In this work, a top-down
approach is employed to realize micron-sized polymeric particles, called
microPlates (uPLs), for the sustained release of therapeutic agents. uPLs are
square hydrogel particles, with an edge length of 20 um and a height of 5 um,
made out of poly (lactic co glycolic acid) (PLGA). During the synthesis
process, the uPL Young's modulus can be varied from 0.6 to 5 MPa by changing
PLGA amounts from 1 to 7.5 mg, without affecting the uPL geometry. Within the
porous uPL matrix, different classes of therapeutic payloads can be
incorporated including molecular agents, such as the anti-inflammatory
dexamethasone (DEX), and nanoparticles, containing themselves imaging and
therapeutic molecules. As a proof of principle, uPLs are loaded with free DEX
and 200 nm spherical polymeric nanoparticles, carrying DEX molecules
(DEX-SPNs). Electron and fluorescent confocal microscopy analyses document the
uniform distribution and stability of molecular and nano agents within the uPL
matrix. This multiscale, hierarchical microparticle releases DEX for at least
10 days. The inclusion of DEX-SPNs serves to minimize the initial burst release
and modulate the diffusion of DEX molecules out of the uPL matrix. The
pharmacological and therapeutic properties together with the fine tuning of
geometry and mechanical stiffness make uPLs a unique polymeric depot for the
potential treatment of cancer, cardiovascular and chronic, inflammatory
diseases.
